4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide 1-hydroxy-2-naphthoic acid (1:1) | 1174325-92-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide 1-hydroxy-2-naphthoic acid (1:1)
• 英文别名: meloxicam 1-hydroxy-2-naphthoic acid；meloxicam 1-hydroxy-2-naphthoic acid (1:1)；meloxicam:1-hydroxy-2-naphthoic acid；4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1lambda6,2-benzothiazine-3-carboxamide;1-hydroxynaphthalene-2-carboxylic acid；4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1λ6,2-benzothiazine-3-carboxamide;1-hydroxynaphthalene-2-carboxylic acid
• CAS: 1174325-92-8
• 化学式: C₁₁H₈O₃*C₁₄H₁₃N₃O₄S₂
• 分子量: 539.59
• InChiKey: DMPJAYQXLMLJAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.19
• 重原子数：
  37
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  194
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  美洛昔康 、 1-羟基-2-萘甲酸 以 四氢呋喃 为溶剂， 生成 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide 1-hydroxy-2-naphthoic acid (1:1)
  参考文献：
  名称：

  In vivo studies of crystalline forms of meloxicam

  摘要：

  本发明涉及美洛昔康的新晶体形式。这些新晶体形式的美洛昔康具有比纯美洛昔康更好的生物利用度，更快的溶解速度和更短的达到血浆Cmax的时间。

  公开号：

  US20090203680A1

文献信息

• [EN] MELOXICAM CO-CRYSTALS<br/>[FR] CO-CRISTAUX DE MÉLOXICAM
  申请人：MYLAN LABORATORIES LTD

  公开号：WO2020095316A1

  公开（公告）日：2020-05-14

  Co-crystals of meloxicam co-formers can be prepared by co-crystallization from a polar solvent, such as aqueous dimethyl sulfoxide; or by slurry processes, such as with ethyl acetate. Such co-crystals have improved purities and are physically stable under storage for several months.

  美洛昔康辅基的共晶可以通过在极性溶剂中共结晶制备，例如水溶性二甲基亚砜；或者通过浆状过程，例如乙酸乙酯。这种共晶具有提高的纯度，并且在存储数月后仍然具有物理稳定性。
• Supramolecular Architectures of Meloxicam Carboxylic Acid Cocrystals, a Crystal Engineering Case Study
  作者：Miranda L. Cheney、David R. Weyna、Ning Shan、Mazen Hanna、Lukasz Wojtas、Michael J. Zaworotko

  DOI：10.1021/cg100514g

  日期：2010.10.6

  Meloxicam is a nonsteroidal anti-inflammatory drug with low aqueous solubility and high permeability prescribed for indications of arthritis, primary dysmenorrhea, fever, and pain, in this contribution, we apply crystal engineering and the supramolecular synthon approach to prepare novel meloxicam cocrystal forms with various pharmaceutically acceptable or toxicologically qualified carboxylic acids. As a result, 19 pharmaceutical cocrystals including one cocrystal of a salt are synthesized by solid-state and solution methods. All resulting cocrystals are characterized by X-ray diffraction. infrared. and thermal analyses. In particular, crystal structures of six rneloxicam cocrystals are determined and reported, namely. meloxicam . 1-hydroxy-2-naphthoic acid cocrystal (1), meloxicam . glutaric acid cocrystal (2), meloxicam . L-malic acid cocrystal lit salt (3), meloxicam . salicylic acid cocrystal form 111 (4), meloxicam . fumaric acid cocrystal (5), and meloxicam . succinic acid cocrystal (6). The supramolecular assembly of each cocrystal is analyzed and discussed. It is observed that the meloxicam dimer is robust since this motif is observed in five out of six meloxicam cocrystal structures that have been determined. As part of the continuous development, the resulting meloxicam cocrystal forms will be further investigated to explore improved physicochemical and pharmacological properties.
• IN VIVO STUDIES OF CRYSTALLINE FORMS OF MELOXICAM
  申请人：Thar Pharmaceuticals Inc.

  公开号：EP2244712B1

  公开（公告）日：2015-08-05
• MELOXICAM CO-CRYSTALS
  申请人：Mylan Laboratories Ltd.

  公开号：EP3877385A1

  公开（公告）日：2021-09-15
• In Vivo Studies of Crystalline Forms of Meloxicam
  申请人：Hanna Mazen

  公开号：US20120149692A1

  公开（公告）日：2012-06-14

  The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to C max in blood, as compared to pure meloxicam.